What is the recommended evaluation and management for a patient with high-risk human papillomavirus (HPV) genotypes 16, 18, and 45?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of HPV Genotypes 16,18, and 45

Patients positive for HPV genotypes 16,18, or 45 require immediate colposcopy regardless of cytology results, with endocervical sampling strongly recommended at the time of colposcopy due to the elevated adenocarcinoma risk associated with these genotypes. 1

Immediate Management Based on Cytology Results

HPV 16/18/45 with Normal Cytology (NILM)

  • Proceed directly to colposcopy even when cytology is negative for intraepithelial lesion or malignancy 1
  • Endocervical sampling should be performed at colposcopy, particularly for HPV 18 and 45, given their strong association with adenocarcinoma 1, 2
  • HPV 16 carries the highest risk, with a 6.9% risk of CIN3+ in cytology-negative women 3
  • HPV 18 has a 2.6% risk and HPV 45 has a 1.1% risk of CIN3+ even with normal cytology 3

HPV 16/18/45 with ASC-US or LSIL

  • Immediate colposcopy is mandatory 1
  • The 2019 ASCCP guidelines specifically recommend colposcopy for HPV 16/18/45 positive patients with ASC-US or LSIL, whereas this was not applicable under 2012 guidelines 1
  • Risk of CIN2+ is 37.0% for HPV 16 and 15.9% for HPV 18/45 in ASC-US patients 4

HPV 16 with HSIL

  • Expedited treatment with loop electrosurgical excision is preferred for non-pregnant patients aged ≥25 years 1
  • Colposcopy with biopsy is acceptable only after shared decision-making with the patient 1

Risk Stratification by Genotype

HPV 16 (Highest Risk)

  • Accounts for the majority of cervical cancers and carries the highest oncogenic potential 5, 3
  • 10-year risk of CIN3 is 21% in cytology-negative women aged ≥30 years 6
  • Immediate colposcopy is recommended in all cases 1

HPV 18 (High Risk for Adenocarcinoma)

  • 10-year risk of CIN3 is 18% in cytology-negative women 6
  • Strongly associated with cervical adenocarcinoma, which is more difficult to detect than squamous lesions 1, 2
  • Endocervical sampling is specifically recommended at colposcopy for HPV 18-positive patients 1, 2
  • Three stage I adenocarcinomas were detected through early colposcopic referral based on HPV 18 genotyping in one study 7

HPV 45 (Intermediate-High Risk)

  • Grouped with HPV 18 in many assays due to similar adenocarcinoma risk 5, 3
  • Recent guidelines classify HPV 45 in the highest oncogenic potential group alongside HPV 16 and 18 8, 5
  • Immediate colposcopy is recommended 5

Follow-Up After Initial Colposcopy

If CIN2+ is Detected

  • Treat according to standard protocols for high-grade lesions 1
  • After treatment, surveillance should continue for at least 25 years with HPV testing or cotesting at 3-year intervals 1

If CIN1 or Less is Found

  • Repeat HPV testing at 12 months is preferred (or cytology at 6 and 12 months) 2
  • If HPV remains positive or cytology shows ≥ASC-US at 1-year follow-up, return to colposcopy 2
  • For HPV 18-positive patients, a lower threshold for treatment is advised if CIN1 persists beyond 12-24 months 2
  • Do not defer the first reassessment beyond 12 months for HPV 16/18/45-positive patients 2

If No Lesion is Identified

  • Annual HPV testing with or without cytology is recommended 1
  • Return to colposcopy if HPV test remains positive or cytology becomes abnormal 1
  • Two consecutive negative results allow return to routine 3-year screening 6

Special Considerations

Surveillance Testing Preference

  • HPV testing or cotesting (HPV + cytology) is preferred over cytology alone for follow-up of HPV 16/18/45-positive patients 1, 2
  • Negative HPV testing is less likely to miss disease than normal cytology alone 1

When Colposcopy is Unsatisfactory

  • If the transformation zone cannot be fully visualized, diagnostic excisional procedure (LEEP, conization) is preferred over ablative methods 2

Unacceptable Management

  • Returning to routine 3-year screening without colposcopy for HPV 16/18/45-positive patients is unacceptable 1
  • Performing ablative treatment without prior endocervical sampling is discouraged 2
  • Deferring colposcopy based on negative prior screening within 5 years does not apply to HPV 16/18/45-positive patients 1

Clinical Pitfalls to Avoid

  • Do not be falsely reassured by normal cytology in HPV 16/18/45-positive patients—colposcopy is still required 1
  • Less than half of patients with HPV-positive/NILM results receive guideline-concordant surveillance testing, leading to delayed cancer diagnoses 9
  • The combination of HPV 16/18/45 with atypical glandular cells (AGC) indicates a 1341-fold increased risk of adenocarcinoma and requires immediate aggressive evaluation 10
  • HPV 18 and 45 adenocarcinomas may be missed on cytology and require endocervical sampling 1, 2, 7

References

1
Guideline

sexually transmitted infections treatment guidelines, 2021.

MMWR Recommendations and Reports, 2021

2
Guideline

Management of HPV 18‑Positive Low‑Grade Cervical Dysplasia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Should I refer a patient with a positive high‑risk HPV (genotypes 16 and 18) test to gynecology for colposcopic evaluation?
What are the management and treatment options for a patient with a positive HPV (Human Papillomavirus) Aptima test result, specifically for Genotype 16, but negative for intraepithelial lesion or malignancy?
What are the management and treatment options for individuals diagnosed with Human Papillomavirus (HPV) 16?
What is the recommended management for a 52-year-old woman with a high‑risk HPV‑16 positive Pap test?
What is the recommended next step for a patient with a normal Pap smear but high‑risk HPV type 16 positive?
What is another name for fatty liver?
Is prescribing meloxicam and methocarbamol appropriate for a patient with right knee spasm and mild osteoarthritis?
Interpret the provided laboratory results, including low serum creatinine, elevated alkaline phosphatase, mild hyperchloremia, and low‑normal carbon dioxide, and explain their clinical significance.
When should a patient experiencing a gallbladder attack (biliary colic) present to the emergency department?
When should intrapartum antibiotic prophylaxis be initiated in a Group B Streptococcus‑positive pregnant woman (≥37 weeks gestation) – at the start of labor or when the membranes rupture?
What cholesterol‑lowering therapy is appropriate for a patient with hyperlipidemia who has a history of throat closure (presumed angio‑edema) while taking atorvastatin?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.